<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="67291">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02113839</url>
  </required_header>
  <id_info>
    <org_study_id>DysPerEx</org_study_id>
    <nct_id>NCT02113839</nct_id>
  </id_info>
  <brief_title>Dyspnea in COPD: Relationship With Exacerbations Frequency</brief_title>
  <acronym>DPE</acronym>
  <official_title>Breathlessness Perception in COPD: Relationship With Exacerbation Frequency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <authority>Spain: Comité Ético de Investigación Clínica</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The perception of breathlessness varies significantly among COPD patients with similar
      severity of airflow limitation; those with poorer perception report less exacerbations as
      compared to those with frequent exacerbations.

      Cross-sectional comparison of breathlessness perception in COPD patients with frequent
      exacerbations  or without frequent exacerbations.

      To assess &quot;Breathlessness Perception&quot; the investigators will increase the ventilatory demand
      of the patients by CO2-rebreathing method.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The perception of breathlessness varies between individuals. This is a well-established
      concept in asthma, but mostly unexplored in COPD; the relationship between airflow
      limitation (FEV1, % ref.) and breathlessness (mMRC) is weak.

      The perception of breathlessness varies significantly among COPD patients with similar
      severity of airflow limitation; those with poorer perception report less exacerbations as
      compared to those with frequent exacerbations.

      It is a cross-sectional comparison of breathlessness perception in COPD patients with
      frequent exacerbations (≥2 or ≥1 with hospitalization in the previous year) or without
      frequent exacerbations (0 or 1 without hospitalization in the previous year).

      To assess &quot;Breathlessness Perception&quot; the investigators will increase the ventilatory demand
      of the patients by CO2-rebreathing method. CO2 rebreathing test will be conducted to
      evaluate the acute ventilatory response to CO2 inhalation used to estimate central
      chemoreceptor responsiveness in patients with the obstructive pulmonary disease.

      Simple descriptive statistics (unpaired T-test) and correlation analysis (bivariate and
      multivariate) will be used to analyze results.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>The negative airway pressure generated during the ﬁrst 100 ms of an occluded inspiration, which is an estimation of the neuromuscular drive to breathe. (P01 )</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Borg scale</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>10-point subjective scoring system, in which a patient rates his/her effort of exertion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fractional exhaled nitric oxide (FeNO)</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inspiratory capacity (IC)</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>The sum of inspiratory reserve volume and tidal volume.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilation at rest</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CO exhaled test</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Testing for Carbon Monoxide in exhaled breath in current smokers.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Dyspnea</condition>
  <arm_group>
    <arm_group_label>No frequent exacerbators</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients without exacerbations: 0 or 1 that did not required hospitalization in the previous year.
Interventions:
Spirometry
Emogas analysis
Modified Borg Dyspnea Scale
CO Exhaled breath
P01
FeNO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Frequent exacerbators</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with frequent exacerbations: ≥2 or ≥1 if it required hospitalization in the previous year.
Interventions:
Spirometry
Emogas analysis
Modified Borg Dyspnea Scale
CO Exhaled breath
P01
FeNO</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Spirometry</intervention_name>
    <description>Before re-breathing (if the patient not performed one 6 months in advance).</description>
    <arm_group_label>No frequent exacerbators</arm_group_label>
    <arm_group_label>Frequent exacerbators</arm_group_label>
    <other_name>FEV1</other_name>
    <other_name>FVC</other_name>
    <other_name>FEV1/FVC</other_name>
    <other_name>VC</other_name>
    <other_name>TLC</other_name>
    <other_name>Rwc</other_name>
    <other_name>DLCO</other_name>
    <other_name>DLCO/VA</other_name>
    <other_name>Ventilation (VE)</other_name>
    <other_name>Inspiratory capacity (IC)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CO Exhaled breath</intervention_name>
    <description>In current smokers of both arms to confirm that the patient has not smoked in the past three hours and to asses the smoking status (heavy, moderate, light).</description>
    <arm_group_label>No frequent exacerbators</arm_group_label>
    <arm_group_label>Frequent exacerbators</arm_group_label>
    <other_name>CO (ppm)</other_name>
    <other_name>COHb (%)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>P01</intervention_name>
    <description>P01 is the negative airway pressure generated during the ﬁrst 100 ms of an occluded inspiration. It's an estimation of the neuromuscular drive to breathe.</description>
    <arm_group_label>No frequent exacerbators</arm_group_label>
    <arm_group_label>Frequent exacerbators</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>FeNO</intervention_name>
    <description>The measurement of fraction of exhaled nitric oxide during exacerbations of COPD is higher than normal.</description>
    <arm_group_label>No frequent exacerbators</arm_group_label>
    <arm_group_label>Frequent exacerbators</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with diagnosis of COPD (Gold 2 or 3 or 4)

          -  &gt;2 months from last exacerbation and no change in therapy

        Exclusion Criteria:

          -  patients on regular sedative drugs

          -  patients with neuromuscular diseases

          -  patients with respiratory failure and/or in long-term oxygen therapy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabel Blanco Vich, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alvar G Agustí, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Clínic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Isabel Blanco Vich, MD, PhD</last_name>
    <phone>+34 649539835</phone>
    <email>iblanco2@clinic.ub.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Clínic</name>
      <address>
        <city>Barcelona</city>
        <state>BCN</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isabel Blanco Vich, MD, PhD</last_name>
      <phone>+34 649539835</phone>
      <email>iblanco2@clinic.ub.es</email>
    </contact>
    <investigator>
      <last_name>Isabel Blanco Vich, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alvar G Agustí, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giulia Scioscia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Felip Burgos, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Davis SQ, Permutt Z, Permutt S, Naureckas ET, Bilderback AL, Rand CS, Stein BD, Krishnan JA. Perception of airflow obstruction in patients hospitalized for acute asthma. Ann Allergy Asthma Immunol. 2009 Jun;102(6):455-61. doi: 10.1016/S1081-1206(10)60117-2.</citation>
    <PMID>19558002</PMID>
  </reference>
  <reference>
    <citation>Miravitlles M, Anzueto A, Legnani D, Forstmeier L, Fargel M. Patient's perception of exacerbations of COPD--the PERCEIVE study. Respir Med. 2007 Mar;101(3):453-60. Epub 2006 Aug 30.</citation>
    <PMID>16938447</PMID>
  </reference>
  <reference>
    <citation>Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest. 2000 May;117(5 Suppl 2):398S-401S. Review.</citation>
    <PMID>10843984</PMID>
  </reference>
  <reference>
    <citation>Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000 May;161(5):1608-13.</citation>
    <PMID>10806163</PMID>
  </reference>
  <reference>
    <citation>Agustí AG, Villaverde JM, Togores B, Bosch M. Serial measurements of exhaled nitric oxide during exacerbations of chronic obstructive pulmonary disease. Eur Respir J. 1999 Sep;14(3):523-8.</citation>
    <PMID>10543270</PMID>
  </reference>
  <reference>
    <citation>Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J; Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007 Sep 15;176(6):532-55. Epub 2007 May 16. Review.</citation>
    <PMID>17507545</PMID>
  </reference>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 14, 2014</lastchanged_date>
  <firstreceived_date>April 4, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>Isabel Blanco</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Dyspnea perception</keyword>
  <keyword>COPD</keyword>
  <keyword>Exacerbations</keyword>
  <keyword>CO2 rebreathing test</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dyspnea</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
